SynthesisNeurosurgical review2025
GammaKnife radiosurgery for meningiomas in neurofibromatosis type II patients: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis type II (NF2) is a genetic disorder marked by the development of multiple CNS tumors, including meningiomas. Managing NF2-associated meningiomas is complex due to the high tumor burden and the need to preserve neurological function. Gamma Knife radiosurgery (GKRS) offers a minimally invasive approach for targeted tumor control, but data on its long-term safety and efficacy in NF2 patients are limited. This meta-analysis assesses the effectiveness of GKRS for NF2 meningiomas, focusing on tumor control, survival outcomes, and adverse effects. This study was conducted according to the PRISMA guidelines. Pubmed (MEDLINE), Embase, Web of Science, and the Cochrane Library databases were systematically searched for studies reporting clinical outcomes of NFII patients with meningiomas treated with GKRS. Data was analyzed using a random-effects model in R Studio. Six studies, comprising 146 patients and a total of 665 meningiomas, met the inclusion criteria. The median age ranged from 32.5 to 40 years, and the median maximum dose administered ranged from 24.5 to 32 Gy. Local progression at the last follow-up was observed in 41 out of 665 tumors (6%; 95% CI 4-9; I²=45%). Five-year overall survival (OS) was 90% (95% CI 79-96; I²=40%). Radiation-induced adverse effects occurred in 22 patients (18%; 95% CI 8-36; I²=70%), of which 20 were transitory. Mortality due to tumor progression was 17% (95% CI 10-28; I²=48%) at the last follow-up, with no reported cases of malignant transformation among treated lesions. These findings suggest that Gamma Knife radiosurgery provides effective tumor control and favorable survival outcomes in neurofibromatosis II patients with meningiomas, with a relatively low rate of local progression and acceptable safety profile.
Indexed as
Identifiers
40237947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.